$1.5M to accelerate drug discovery within the Quebec-Ontario Life Sciences Corrido

$50 million to support biotech companies

15th of CQDM.

2021 Sweet Pharma Day Winner is HDAX Therapeutics

2023 Sweet Biopharma Day Winner is Epitopea!

2024 OBIO Investment Summit

2nd Annual Gordon Shore Prize - Postdoctoral Internships in the Biopharmaceutical Industry

2nd Annual Gordon Shore Prize – Call for Proposal to Private Companies

2nd edition of Connect-Pharma : Pitch day.

3rd edition of Connect-Pharma : Pitch day.

4,000 subscribers to our LinkedIn page

48Hour Discovery and Merck initiate drug discovery project - Project funded through CQDM Quantum Leap program

4th edition of Sweet Biopharma Day – Call for entries now open

A 150-plex affinity proteomics platform for high throughput and high content phenotypic cell screening

A 5th competition for the Quebec/France Program

A Blood-Brain Barrier Carrier Platform for Delivery of Multiple Classes of Therapeutics for Treating CNS Diseases

A Drug Screening Platform to Increase Protein Expression Levels for Treatment of Neurological Disorders

A genetic test to predict diabetic nephropathy in Type 2 diabetes patients

A new partnership between CQDM, the Canadian Cancer Society, the Cole Foundation and Oncopole to support pediatric cancer research

A new platform to Assess Antigen Destruction and Evaluate the Efficacy of Immunotherapies and Vaccines

A novel phage-based screening technology for antiviral

A Novel Platform Combining Transcriptomics and Interaction Proteomics to Better Define Personalized Medicine in Cancer

A Novel Raman-Based Multiplex Imaging Platform to simultaneously detect up to 15 Breast Cancer Biomarkers

A project funded by CQDM redefines the treatment of cancer

A research project originally funded by CQDM and Brain Canada leads to a new partnership between the Centre for Drug Research and Development (CDRD), the Montreal Neurological Institute and Hospital at McGill University (MNI), and Merck

A Screening Technology to Improve the Discovery of Function-Modifying Antibodies Against Membrane Protein Targets

A Zebrafish-Based Platform for Nuclear Receptor Drug Screening and Pathway Discovery in Metabolic Disease and Cancer

Accelerating the transition from idea to market - Submission of the RSRI brief

Access funding for your RD projects with the support of conscience and CQDM

Acting on membrane protein-protein interactions: Mammalian Membrane Two Hybrid (MaMTH) as an Innovative Technology for Drug Discovery Against Protein- Protein Interactions

ADRIQ 2022 Award – Warmest congratulations to Steven LaPlante of INRS and NMX Research and Solutions, winners of the Industrial Sectoral Research Group Award (RSRI) presented by CQDM!

ADRIQ* 2021 AWARD – CQDM congratulates Feldan Therapeutics for receiving the 2021 ADRIQ RSRI (regroupements sectoriels de recherche industrielle) award.

AI and drug development

Ali Tehrani appointed on CQDM’s Board of Directors

Alzheimer’s Disease Mouse Model Characterization: Correlation Between MRI and ex vivo Immunohistochemistry

Amgen and Takeda join the Quantum Leap project led by CQDM and Feldan Therapeutics

Amgen becomes a new member of CQDM to further the development of cutting-edge drug discovery

Announcement - The therapeutic potential of a marine oxygen carrier

Announcement - World Cancer Day

Announcement – Development of a New Diagnostic Technique for Targeted Treatment of Breast Cancer

Announcement – Innovative Treatments for Diabetic Kidney Disease

Announcement – Rare Disease Day

Announcement – Research project promoting cellular rejuvenation

Announcement of a new funding from the Government of Canada

Announcement of an investment of close to $8 million dollars in biopharmaceutical research in Québec

Appointments to the CQDM Board of Directors.

Artificial intelligence-driven nerve identification and decision support-assisted regional anesthesia

Artificial Liver for Safer and more Effective Drugs: Three-Dimensional Liver Tissue Models for High-Throughput Screening of the Efficacy and Hepatotoxicity of Drugs

Automated Zebrafish High Throughput Drug Screening Platform: An Automated Zebrafish High Throughput Technology to Accelerate in vivo Screening of Small Molecules in Disease Models

Axelys and the sector-based industrial research clusters are joining forces to boost innovation in Quebec for the benefit of research centers, businesses and society.

Bacterial ATP synthase inhibitors – A novel approach toward antibiotics targeting difficult-to-treat Gram-positive and Gram-negative bacterial infections

Become a CQDM Member.

Bernard Massie and Cameron Black appointed to CQDM’s Scientific Advisory Board

Biomarkers Discovery in Diabetes: New Biomarkers for Measurement of Early Stage Diabetes Disease and for Prediction of Response to Therapy

BIOQuébec, QCDD, NEOMED Institute, Montréal InVivo and Rx&D call on political parties to spell out their intentions and priorities for the life science sector

Blood-based biomarkers to diagnose neuroendocrine tumors, follow disease progression and identify new therapeutic targets

Call for Applications for the Gordon Shore Prize - Internships for new graduates

Call for collaborative research projects on precision care in oncology

Call for ideas: driving innovation in personalized medicine through translational research and collaboration.

Call for Proposal to Private Companies - Post-Diploma Internships Co-Funded through the Gordon Shore Prize

Call of ideas : Driving innovation in personalized medicine through translational research and collaboration

Canadian Cancer Society and CQDM announce a partnership of $5 million for breast cancer research in Quebec

Catecholamine-Regulated Protein 40 (CRP40) as a New Candidate Biomarker for Early Diagnosis of Parkinson’s Disease

Circumventing the need for predictive biomarkers in personalized ovarian cancer therapies: empirical chemosensitivity testing using a microfluidics-based multiplex platform

Collaborative project of more than $1.2 million using artificial intelligence to optimize the production of vaccines, announced by CQDM and Medicago R&D

Collaborative R&D – a Catalyst of Innovation for Biopharmaceutical Companies

Communicating Life Sciences to the Public: Winners of “Tweete tes neurones!” challenge pitch in

COMMUNICATIONS AND MARKETING COORDINATOR

Competition results 2008-2009 (letter of intent)

Computational and machine learning approaches to improve design and screening of peptides in drug discovery

Congrats Sandra!

Congratulations Alexandre Morizot.

Congratulations Sandrine Campeau

Congratulations Université Laval

Connect-Bio : Collaborations to Propel Innovation in Neuroscience

Connect-Pharma: Pitch Day

Contribution from the MEI ($3.3M) allows CQDM to support 5 biopharmaceutical research projects ($15.5M)

CQDM 2014 Activity Report: A year of partnerships

CQDM 5 years already and many achievements!

CQDM acknowledges the success of the Forum Québécois des Sciences de la Vie which was organized by the government of Quebec

CQDM and a group of partners are launching the CELLULE to accelerate the development of RNA therapies in Quebec

CQDM and Brain Canada Inject $1 M in Top BC Biotech Firm AbCellera to Advance Discovery Platform for Next-Generation Antibody Therapeutics

CQDM and Defence Therapeutics fund the development of a new cancer vaccine platform

CQDM and Epitopea Fund the Development and Validation of CryptoMapTM a Supportive Platform Enabling the Development of RNA-based Immunotherapies

CQDM and Génome Québec joins to launch le Défi « Tweete tes neurones »

CQDM and NanoGene Therapeutics Fund the Development of a Treatment for Psoriasis

CQDM and OCE co-fund a promising research collaboration in neuroscience

CQDM and Sanofi Canada partner to accelerate drug discovery

CQDM and SPM Therapeutics fund a study carried out by Professor Boilard at the CHU de Québec-Université Laval to develop a treatment for systemic lupus erythematosus

CQDM and the Canadian Cancer Society commend Theratechnologies and UQAM for their success in developing a new therapy against the most aggressive form of breast cancer

CQDM and the Massachusetts Life Sciences Center announce a new international partnership program

CQDM and the Sorintellis Group fund the development of an AI-powered platform to mitigate clinical trial risks

CQDM announces a new initiative to stimulate innovation and entrepreneurship in the RNA therapy sector in Quebec

CQDM announces funding to develop a test to predict disease progression in patients infected with COVID-19

CQDM Announces New Member to its Precompetitive Research Consortium to Accelerate Drug Discovery: Janssen Inc.

CQDM Announces the Arrival of Carl Baillargeon in its Team

CQDM announces the creation of a biomanufacturing services platform to boost expertise in Quebec and accelerate the development of RNA therapies

CQDM announces the creation of training programs to meet the needs of the RNA therapeutics industry

CQDM appoints Brian Underdown as the Chair of its Scientific Advisory Board (SAB) and nominates 3 new SAB members

CQDM Awards a Grant to Centre de Recherche du CHU de Québec-Université Laval ...

CQDM becomes a shareholder of Mesentech to support the validation of a highly promising bone-targeting drug delivery technology

CQDM congratulates recipients of the second call for projects from the Fonds d'accélération des collaborations en santé (FACS)

CQDM Congratulates Theratechnologies and Professor Borhane Annabi from UQAM.

CQDM funds a collaborative research project between the RI-MUHC and Divocco AI to develop an artificial intelligence-driven technology that improves regional anesthesia

CQDM Funds a Project Aiming to Elucidate the Effets of Psilocybin on Neuronal Circuits in Order to Treat Depression

CQDM funds a project to improve the screening of lung cancer with BioMark Diagnostic Solutions, in partnership with AstraZeneca, Pfizer Canada and the IUCPQ Foundation

CQDM funds an innovative project with Altus Formulation and Tetra Bio-Pharma to develop first-in-class treatments for ocular inflammation

CQDM Funds Four Projects to Transform Innovation Into Promising Medical Solutions

CQDM funds the development of a novel artificial intelligence tool for cardiovascular clinical trials

CQDM grants $1.15 M in funding to Professor Yves St-Pierre’s team to develop a revolutionary immunotherapy against breast cancer

CQDM initiates a unique collaboration with Merck, Pfizer and Biospective on Alzheimer’s disease

CQDM invests $500,000 in Giiant Pharma, a Quebec-based pharmaceutical company with strong potential in gastroenterology

CQDM invests in Montreal-based regenerative medicine company, Morphocell Technologies

CQDM is proud to announce a new collaboration / broadcast / communication partnership with OBIO.

CQDM is proud to announce an investment of $1.5 M in two collaborative projects from the Québec/Ontario corridor

CQDM is proud to be part of Optina Diagnostics' success

CQDM is proud to contribute to the success of Medicago and its partners, winners of the 2020 RSRI Innovation Award from ADRIQ

CQDM is proud to present a new series of events: Connect-Pharma

CQDM is proud to welcome our new Network Member: RNA Technologies and Therapeutics!

CQDM is recruiting! Interested in a summer Internship position in Administration and Accounting? Apply now!

CQDM joins forces with Neurasic Therapeutics, CSVS and the Louise and Alan Edwards Foundation to fund the development of a non-opioid analgesic

CQDM nominates John Delaney and Jennifer Hamilton as Scientific Advisory Board members

CQDM nominates Kuldeep Neote as Scientific Advisory Board member

CQDM partners with GlycoNet to support innovative Glycomics research in Canada

CQDM Partners with MaRS Innovation, Ontario Brain Institute and Ontario Centres of Excellence to Launch Life Sciences Funding Program Within Ontario-Québec Corridor

CQDM portfolio company Mesentech secures new capital to bring lead product to clinical phase

CQDM receives funding of $ 11.7 M from the Federal Government

CQDM receives the Innovation Price during the "Fête Champêtre 2010" of the Fondation Armand-Frappier

CQDM sets up a collaboration between Simon Fraser University, Amgen, Merck, Servier and GlycoNet

CQDM SynergiQc program now includes an additional section on breast cancer, in collaboration with the Canadian Cancer Society

CQDM to fund an international collaboration between Raya Therapeutic, Eikonizo Therapeutics and McGill University

CQDM to fund an international collaboration between Traffick Therapeutics, McGill University and the Lead Discovery Center

CQDM to support a $1.1 M R&D project for Immune Biosolutions’ next-generation of anti-cancer treatment

CQDM welcomes 3 new ''Network'' Members.

CQDM Welcomes Eli Lilly Canada, A Leading Innovative Pharmaceutical Company, to Support the Explore Program

CQDM welcomes its new member "Network" VVector Bio!

CQDM welcomes Novartis as a new contributing member to the Explore Program

CQDM welcomes the update of the Quebec Life Sciences Strategy

CQDM welcomes two additional Pharma members, Boehringer Ingelheim and GlaxoSmithKline Inc.

CQDM welcomes two new pharma members to its biopharmaceutical research consortium

CQDM welcomes Zymeworks as a new member of CQDM’s biopharmaceutical consortium

CQDM will be in Quebec City on October 10 to present its financing programs

CQDM will partner with Feldan Therapeutics to support a $1.2M project, to improve a novel intra-cellular delivery technology

CQDM will receive a grant from the BL-NCE to research better ways of developing and testing drugs that treat central nervous system diseases

CQDM, Diazon and the Oncopole in collaboration with Mitacs announce the creation of a prize of excellence for graduate students in cancer research in memory of Professor Gordon Shore

CQDM, Diazon and the Oncopole in collaboration with Mitacs announce the two laureates of the 2019 Gordon Shore Prize

CQDM, Feldan Therapeutics and Amgen fund development of innovative drug delivery technology to target lung diseases

CQDM, HBHL, Corbin Therapeutics and Brain Canada award $1.5 M to McGill Prof. Philippe Gros

CQDM, MEDTEQ+ and Montréal InVivo partner with IVADO to promote digital health innovation

CQDM, the CCS and Theratechnologies grant $1.7M to UQAM in breast cancer research

CQDM, the Quebec Breast Cancer Foundation and Theratechnologies fund close to $2 million for research project to validate the anti-metastatic potential of TH1902 at the Université du Québec à Montréal

CQDM's 2015 Activity Report: A toolbox of success

Creation of a global hub for RNA-based therapies in Quebec

Cycloinformatics: A Platform to Rapidly Produce Macrocyclic New Chemical Entities to inhibit Protein- Protein Interactions

Cyto-iGluSnFR: A glutamate biosensor platform for brain diseases

Défi Tweete tes neurones! - Optimum Vice President and general manager, Isabelle Perras, agrees to act as president of the jury

Defining the Rules That Will Enhance the Cell Permeability and Oral Bioavailability of Macrocycles

Design and Characterization of Feldan Shuttle Peptides and Derivatives as Pulmonary Delivery Agent

Detection of Molecular Interaction Field Similarities for the Rational Drug Design of Multi-Functional Inhibitors

Developing New Alzheimer’s Therapeutics Using a Novel Carrier That Can Cross the Blood-Brain Barrier

Developing open access protein degradation tools for drug discovery

Development and Evaluation of a Multimodal Approach to Predict Lung Cancer Risk and Determine EGFR Mutation Profile in a Lung Cancer Screening Population

Development of a high throughput 3D microphysiological platform for rapid automated assessment of human brain organoids response to drugs targeting neurological disorders

Development of a high throughput bioprinted 3D human tumor microenvironment assay that recreates immune “hot” and “cold” tumors

Development of a machine learning-based in-process quality monitoring technology for plants during vaccine manufacturing

Development of a new class of oral and highly potent non-statin LDL-cholesterol lowering therapeutics for patients at high cardiovascular risk

Development of a New Matrix for Pancreatic Islets Culture and its Validation in a Bioartificial Pancreas

Development of a personalized living chicken embryo avatar model to predict chemotherapeutic drug sensitivity/resistance

Development of a Variant-Agnostic COVID-19 Protein Antigen Candidate for a Intranasal Vaccine

Development of immunotherapy for bladder cancer using IMV’s drug delivery platform

Development of inhibitors for CUX1 and PARG, two novel therapeutic targets for hard-to-treat breast cancers

Development of novel biologic inhibitors of Semaphorin3A for the treatment of retinal vascular diseases.

Development of novel immunotherapeutic approaches targeting gene fusion-derived neoantigens to cure pediatric acute leukemia

Development of novel targeted therapies and diagnostic tools for high risk pediatric leukemias

Development of pharmacological correctors for Alpha-1 antitrypsin deficiency (ATD) using VIPER

Diane Gosselin appointed President and Chief Executive Officer of CQDM

Dimer Interference: A novel Approach to Develop Galectin-7-Specific Inhibitors to treat Triple-Negative Breast Cancer

Discovery of analgesic drugs targeting the acid-sensing ion channel family

Domain Therapeutics, Université de Montréal, IRICoR and McGill University sign new licensing and partnership agreement on G-Protein Coupled Receptor biosensor technology

Drive innovation and performance by integrating equity, diversity, and inclusion

Drug-enabling technology innovations get boost through OCE-CQDM Life Sciences R&D challenge

Encycle Therapeutics Launches Ground-Breaking Chemistry Platform

Encycle Therapeutics working with major pharmaceutical companies to design rules for drugs meant to be swallowed

Engineering Endogenous Vesicles as a Drug Delivery Platform to Inhibit Gene Expression Using microRNAs and Silencing RNAs

Establishing a world-class biophysics platform that will enable and accelerate the discovery of leads for launching drug-discovery programs

Exploitation of a new pharmacological target for the development and validation of new anti-inflammatory drugs

Facilitating Anti-Cancer Drug Discovery with Selective Inhibitors to Modulate the Protein Ubiquitination Process

First research project to be funded under the Canada/Germany Program

First-In-Class Melatonin MT2 Receptor Agonist for Neuropathic Pain: Investigational New Drug (IND) – Enabling Studies

FlAsH-Walk Mapping: An Innovative Step-by-Step Approach to G Protein-Coupled Receptor Conformation Cartography

Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences

Fragment-Based Lead Discovery: Bridging the Gap Between Screening and Hit-to-Lead Medchem using NMR Affinity Ranking

Funding activities carried out in companies that are part of collaborative R&D Projects in Artificial Intelligence

Genetic testing to guide therapeutic decision in diabetic patients of various ethnic backgrounds

Germany and Canada join forces to enhance biopharmaceutical R&D internationally

GlycoNet and CQDM collaborate to boost drug discovery and develop new health solutions for Canadians

GRANTS MANAGEMENT AND COMPLIANCE COORDINATOR

Health Innovation: Investing Now to Face the Crises of Tomorrow

Hope on the horizon for hard-to-treat breast cancers

Identification of T Cell Receptor Somatic Mutations Driving Autoimmunity in Human Rheumatoid Arthritis

Identification of Tumor Specific Antigens to Develop Therapeutic Vaccines Against Acute Myeloid and Lymphoid Leukemias

IMV and CRCHU de Québec-U Laval Collaboration Awarded a CQDM Grant to Develop First-in-class Dual Target T cell Therapy in Bladder Cancer Based on IMV’s DPX Technology

In vivo demonstration of potency to improve impaired efferocytosis and control inflammation related to Systemic Lupus Erythematosus (SLE)

In-vivo Solid Phase Microextraction Integrated with Mass Spectrometry Platform for Untargeted and Targeted Investigation of the Brain

Inducible human pluripotent stem cells to better understand and treat Parkinson’s disease and ALS

Inducible Mouse Models to Accelerate Drug Development for Parkinson’s Disease and Other Synucleinopathies

Industrial research clusters congratulate new Minister of the Economy and Innovation

Innervated, Vascularised and Immunocompetent Human Skin Model for Screening the Sensitization Potential of Chemicals

Innovative immunotherapy using Chimeric Antigen Receptor (CAR) in hematopoietic stem cells for pediatric acute lymphoblastic leukemia and rhabdomyosarcoma

Innovative Optical Imaging and Bio-Simulation Platforms to Accelerate Central Nervous System Drug Discovery

Integrating Functional and Genomic Profiling for Optimal Combination Therapies for Cancer Patients

Integrating Tumour-Microenvironment Biomarkers to Improve Diagnostic and Facilitate Targeted Breast Cancer Therapy

Intracellular delivery of antibodies and peptides using a peptide-based technology

IPPER, the Integrated Platform for the Pharmacology of the Endoplasmic Reticulum and protein trafficking diseases

JOB OFFER - ADMINISTRATIVE ASSISTANT

JOB OFFER - DIRECTOR SCIENTIFIC AFFAIRS

JOB OFFER - SENIOR DIRECTOR ACCOUNTING AND FINANCE

Julie Martineau appointed as Senior Director, Communications and Corporate Development of CQDM

Life sciences and health technologies should be the focus of Quebec’s next research and innovation policy

Live Cell Imaging System for Protein-Protein Interactions: Multiplexing Fluorescence Lifetime Imaging: a rapid HCS system to study protein-protein interactions in live cells

Lyonbiopôle, CQDM and Alsace BioValley organize the first joint networking event in Lyon to encourage the emergence of French-Quebec projects.

Macrocyclic peptides as the next-generation immuno-oncology therapeutics

Magnetically Guided Bacteria to Specifically Deliver Anti-Cancer Agents to Colorectal Cancer Sites

Make a difference! Job Opportunity: controller

Mapping Genetic Interactions: A Path to Discover Efficacious Drug Targets

Mario Chevrette appointed Vice President, Scientific Affairs of CQDM

McGill, industry, CQDM and Brain Canada collaborate for drug discovery

Merck Canada Invests $5 Million in Quebec Consortium for Drug Discovery to Support Biopharmaceutical Research

Merck Canada reaffirms its commitment to CQDM with a $3.5M contribution to sustain innovation in Life Sciences

Merck Canada reaffirms its commitment to CQDM with $3M in funding to support biopharmaceutical innovation.

Michel Goldman appointed member of CQDM’s Board of Directors

Monitoring Conformational Changes in Channel Proteins: A Novel Approach for Rapid Screening of Ion Channel Hits

Monitoring the Signaling Pathways of G Protein Coupled Receptors in Living Animals to Accelerate Drug Discovery

Multimodal digital biomarkers for the identification of companion diagnostic tools in cardiovascular diseases.

Neomabs Biotechnologies, a company dedicated to developing new immunotherapies for cancer treatment launches in Montreal

Neuro-CERVO Alliance partners with Simmunome, a Montreal-based artificial intelligence company

New appointments to CQDM’s Board of Directors and Scientific Advisory Board

New call for proposals under the Fonds d’accélération des collaborations en santé

New funding opportunity for research on the brain!

New funding opportunity for RNA therapies!

New funding opportunity for your regenerative research projects

New GPCR-Specific Biosensor Technology to Monitor Cellular Events Associated with Drugs Efficacy and Side Effects

New Network Member: Simmunome

New partnership with ADRIQ.

New partnership with Axelys.

New partnership with Centech.

New partnership with IVADO.

New partnership with the Canada Foundation for Innovation via its Research Facilities Navigator.

New Processes Mimicking the Spray drying technique for the Preparation of Thermally Stable Vaccines

NEW PROGRAM: SYNERGIQC

Non-Invasive Diagnostic Test Using Electroretinography for Profiling Patients with Schizophrenia and Bipolar Disorders

Nouveau partenariat avec BIOQuébec.

Novel Drug Development Tools to Interrogate the Role of Galectins in Breast Cancer

Novel in silico-assisted Platform to Rapidly Enhance Specificity and Affinity of Therapeutic Antibodies Against Their Targets

Novel Methods to Evaluate Cardiac Activity of Pharmaceuticals: Identifying New Therapies and Predicting Cardiac Toxicity

Novel Non-Invasive Laser-Assisted Intraocular Drug Delivery System for an Efficient and Selective Gene Transfer Therapy

Novel p53-activiting MDM2 inhibitor oncology platform therapy

nplex-McGill partnership selected by CQDM for a $1M grant to apply next-generation ELISA in drug discovery

OCE and OBI are partnering with CQDM to the tune of 3 million dollars in innovative inter-provincial drug discovery programs.

Opportunity of Biopharma Networking during the “Connect-Bio: Médecine personnalisée” event in 22 days.

Optimizing the monitoring of patients with DLBCL

Outside the box in neuroscience: CQDM and Brain Canada partner to fund breakthrough technologies to accelerate drug discovery

Parkinson's disease: a first research collaboration between CQDM and Massachusetts

PARTENAR-IA - * New * Grants for IA research projects applied to the biopharmaceutical sector

Partnership agreement between CQDM and Alsace BioValley

Patrick Wier and Jorge Puente appointed to CQDM’s Board of Directors

Personalized medicine: CQDM and CIHR fund two promising research collaborations aligning academic and industrial research

Personalized medicine: CQDM partners with CIHR to accelerate drug discovery across Canada

Pfizer Canada renews its support to CQDM with a $550,000 contribution

Phase II clinical and translational study of neoadjuvant pembrolizumab for personalization of prostate cancer treatment

Philip Tagari Appointed to CQDM’s Board of Directors

Philippe Walker appointed Member of the Scientific Advisory Board of CQDM

Philippe Walker is appointed chairman of CQDM’s Strategic Orientation Committee

Photo-album of our event on November 26th, 2008

Platform for the enrichment of circulating tumor cells (CTCs) for characterization and sensitivity to anti-cancer drugs

Platform to target small-molecule therapeutics to bone – Novel prodrugs to selectively deliver therapeutics to bone

Postponed deadline to submit a SynergiQc project

Pre-budget Consultations: 3 proposals from CQDM to boost Quebec's economy

Pre-clinical design of a novel targeted and personalized treatment against Sortilin-positive triple negative breast cancers

Pre-launch of a new call for proposals in June 2020: discover the latest updates!

Preclinical assessment of aspartyl protease inhibitors as an antifungal therapeutic strategy

Predict lung cancer risk.

Press Release: Michele D’Elia and Pierre Côte Join CQDM’s Board of Directors.

Project funded through CQDM will explore potential of Fusion Genomics’ ONETest™ to improve diagnosis of respiratory tract infections

PROJECT MANAGER

Prospective evaluation of the ONETest™ targeted metagenomic platform to identify respiratory tract pathogens for precise diagnosis and clinical trial recruitment

Proud to announce Veronique is now chief of operations COO at CQDM

Public/Private Partnerships and New Models to Stimulate Innovation: Examples from Quebec and Massachusetts

PulmoBind: A Biomarker for Diagnosing Pulmonary Hypertension

PulmoBind: A New Non-Invasive Marker for the Early Diagnosis of Patients with Pulmonary Hypertension

Quantum Leap - Program Opened

Quebec announces an investment of $9 Million for CQDM

Québec Launches AReNA to Become a Global Leader in RNA Therapies

Québec Research and Innovation Investment Strategy 2022-2027

QUO2 MRI: Quantitative Measurement of Metabolic and Vascular Anomalies in the Brain of Alzheimer’s Disease Patients

RecyTag technology for extended half-lives of small biologics

Rémi Quirion joins the CQDM Board

Research and development of an antimetastatic peptide conjugate of docetaxel (TH1902) against sortilin positive cancers

Research project

Richard Fajzel appointed new Chairman of CQDM’s Board of Directors

SAVE THE DATE / Bio+ech Connec+ event taking place on Wednesday March 16th

Scientific days of the CRCHUM.

Selectomics to monitor and predict the emergence of resistance to antibiotics by using the human microbiome

SEVEN EXCEPTIONAL GRADUATES HONORED BY THE SCHOOL

SEVEN GRADUATES WHO MAKE ESG UQAM PROUD

ShARP: Screenable Assays for RNA-Binding Proteins Involved in Brain Disorders

Six new drug discovery acceleration projects supported by CQDM and Ontario Centres of Excellence showcase continued success of Quebec-Ontario Life Sciences Corridor

Subscribe to our newsletters

Success of a preclinical study against breast cancer.

Supporting innovation is essential to our prosperity

Sweet Biopharma Day’s 3rd Edition | Québec, Canada Call for startup proposals, now open

SynergiQc-International: New funding opportunity for public-private biopharmaceutical research

Synthetic lethality platform to discover, test and validate new therapeutic treatment options for cancer

Targeting the Right Cells: Human MiniPromoters for Restricted Gene Expression in Specific Cells of the Eyes

Testing an Accum-Reprogrammed Mesenchymal stromal cell (ARM) melanoma vaccine

The 10th anniversary of CQDM.

The 4th edition of the innovative partnership forum organized by the CQDM and Montréal InVivo was a huge success

The Canadian Cancer Society, CQDM, the Cole Foundation and Oncopole grant close to $8.5 million to four researchers in Quebec to support pediatric cancer research

The Canadian Cancer Society, the Quebec Breast Cancer Foundation and CQDM join forces to fight breast cancer

The CCS, CQDM and biotech companies will invest nearly $10M to support 3 breast cancer research projects

The CQDM and Univalor have announced a collaboration agreement

The CQDM joins Genome Québec and the Ontario Genomics Institute for a partnering event in Toronto

The CQDM launches its first call for proposals

The Encapsulated Liver Tissue as a treatment for acute liver failure: proof-of-concept efficacy and safety in large animals using liver organoids composed of primary cells

The eye: a window to the brain – Detection of Alzheimer’s Disease in the Prodromal Stage from Non-Invasive Hyperspectral Retinal Images

The first CQDM funded project is a remarkable success – Thanks to CQDM funding, Medicago announces an important investment in Québec

The French BIO-clusters Lyonbiopole and Alsace BioValley and CQDM join forces to foster R&D collaboration and emergence of France-Quebec projects

The project led by Michel Bouvier and Domain Therapeutics with the support of CQDM is awarded the RSRI Recognition Award at the ADRIQ Innovation Prize Gala

Theratechnologies Unveils New Positive Data For Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers

Three new appointments to CQDM

To see and hear...souvenir video of our 15th anniversary

Topic nanovectors for targeted gene therapy of cutaneous psoriasis

Towards the Development of a New Class of Anti-GPCR Antibodies for the Treatment of Aggressive Cancers

Treatment of Hirschsprung disease by rectal administration of neurotrophic factors.

TRIple negative breast Cancer markers In liquid biopsies using Artificial intelligence (TRICIA study)

Unlocking a class of challenging drug targets using a next generation screening and lead development platform technology

Unprecedented mobilization of Quebec's research and innovation ecosystem against COVID-19

Using Patient’s Blood to Develop a Sensory Neuron-Based Platform to Treat Chemotherapy-Induced Peripheral Neuropathy

Uwe Schoenbeck from Pfizer Inc. appointed member of CQDM’s Board of Directors

Validation of KQ-791 in combination immunotherapies cancer models

VIPER, the lentiviral IPPER platform for drug discovery in trafficking diseases. IPPER-accelerated development of pharmacological correctors for cystic fibrosis

VLPExpress®: Novel high-throughput discovery platform to accelerate the development of new vaccines based on Virus-Like Particles

Wallonia (Belgium) and Canada join forces in a new international initiative to improve biopharmaceutical R&D

We are hiring! Manager – Communications & events - Apply now!

We are hiring! Project Manager - Apply now!

We are looking for the winning formula: administrative coordinator position

We are looking for the winning formula: Communications and Marketing Coordinator

We are looking for the winning formula: job offer! ACCOUNTING TECHNICIAN

We are looking for the winning formula: job offer! ADMINISTRATIVE ASSISTANT

We are looking for the winning formula: job offer! CHIEF ACCOUNTANT

We are looking for the winning formula: job offer! FINANCIAL CONTROLLER

We are looking for the winning formula: job offer! Project manager

We are looking for the winning formula: job offer! SENIOR BUSINESS DEVELOPMENT POSITION, PHARMACEUTICAL PROGRAMS

We are RECRUITING for a Communication position: Director of Communications and Public Relations - CQDM (Deadline to apply: January 27th)

We are RECRUITING: General Director for Early Stage Clinical Trial

We are RECRUITING! Interested in a Controller position? Apply now!

We need your precious collaboration

Welcome Annie Bernier.

Welcome Aren!

Welcome Catherine-Alexandra.

Welcome Dorothy!

Welcome to Julia Serafino

Zealand Pharma’s acquisition of Encycle Therapeutics highlights the impact of CQDM’s early support

Zebrafish High Throughput Screening Platforms for Nuclear Receptor-Related Drug Discovery and Pathway Elucidation

Site Map

Pages